Clinical Trial Update: Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

View source ↗

Summary

Expanded access program using mesenchymal stromal cells to treat MIS-C associated with COVID-19 is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multisystem Inflammatory Syndrome in Children

Drugs mentioned

• Mesenchymal Stromal Cells (MSC) (mesenchymal stromal cells)

Snippet

Sponsor: Mesoblast International Sàrl | Conditions: Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19) | Status: NO_LONGER_AVAILABLE